CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DECEMBER 2019

	T				(Dune	!- mi		
	Quarter Ended Nine Months Ended V. D. J.							
Sr. Particulars I Revenue from Operations				Nine Months Ended		Year Ended		
	2019	2019	31st Dec., 2018	31st Dec., 2019	31st Dec., 2018	2019		
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited			
			100 0000					
	1,499	2,779	1,420	7,109	3 959	8,225		
	1,499	2,779	1,420			8,225		
					5,5-5-	0,220		
. ,	-	-	-	-		100		
(2) Purchase of Stock-in-Trade	-	-						
Stock-in-Trade	-	-	-	-	-			
(4) Employee Benefits Expenses	574	430	624	1,409	1.692	2.216		
(5) Depreciation and Amortisation Expenses	-	-		1,105	1,092	2,218		
(6) Administrative and Other Expenses	242	564		1.740	1.407	2.414		
i) Professional Charges	-	-		2,1.10		3,414		
		-		-				
iii) Share Registry Expenses		-	269					
	-	-	-					
	-	-	-	-				
	816	994	1,302	3,149		F 670		
and tax (III - IV)	683	1,785	118	3,960	(364)	5,679 2,546		
	-							
VI)	683	1,785	118	3,960	(364)	2,546		
	-	-						
The state of the s	683	1,785	118	3 960	12641	0.546		
				- 0,500	(304)	2,546		
		-	-			160		
	-	-	_			460		
	-	-				23		
X)	683	1,785	118	3,960	(364)	2,063		
Profit/(Loss) from discontinuing operations	-							
Tax Expenses of discontinuing operations		-				-		
Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-			-	-		
Profit/(Loss) for the period (XI - XIV)	683	1 705	110					
Other Comprehensive Income	000	1,785	118	3,960	(364)	2,063		
A (i) Itmes that will not be reclassified to profit or loss								
(ii) Income rax relating to items that will not be reclassified to profit or loss						7 - 1		
B (i) Itmes that will not be reclassified to profit or loss								
fotal Comprehensive Income for the period (XV+XVI)					-			
(Comprising Profit (Loss) and Other Comprehensive Income for the period	683	1,785	118	3,960	(364)	2,063		
Larnings per Share :								
(1) Basic (2) Diluted	0.46	1.19	0.08	2.64	(0.24)	1.38		
I I I I I I I I I I I I I I I I I I I	Revenue from Operations Other Income Total Revenue (I + II) Expenses (1) Cost Materials consumed (2) Purchase of Stock-in-Trade (3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade (4) Employee Benefits Expenses (5) Depreciation and Amortisation Expenses (6) Administrative and Other Expenses (7) Professional Charges (8) ii) Annual Listing Fees (8) iii) Share Registry Expenses (9) Postal Charges (17) Finance Costs Total Expenses Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV) Exceptional Items Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI) Extra Ordinary Items Profit/(Loss) before Tax (VII-VIII) Tax Expenses (1) Current Tax (2) Tax Adjustment Previous Year (3) Deffered Tax Profit/(Loss) for the period from continuing operations Tax Expenses of discontinuing operations Profit/(Loss) from discontinuing operations Profit/(Loss) for the period (XI - XIV) Other Comprehensive Income A (i) Itmes that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be reclassified to fortal Comprehensive Income for the period (XV+XVI) Comprising Profit (Loss) and Other Comprehensive Income for the period (XV+XVI) Comprising Profit (Loss) and Other Comprehensive Income for the period (XV-XVII)	Revenue from Operations Other Income Other Income Other Income Other Income Total Revenue (I + II) I,499 Expenses (I) Cost Materials consumed (2) Purchase of Stock-in-Trade (3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade (4) Employee Benefits Expenses (5) Depreciation and Amortisation Expenses (6) Administrative and Other Expenses (1) Professional Charges (1) Professional Charges (2) Professional Charges (3) Professional Charges (4) Professional Charges (5) Depreciation and Amortisation Expenses (6) Administrative and Other Expenses (7) Finance Costs Total Expenses (8) Profit/(Loss) before Exceptional and Extra ordinary Items and tax (II - IV) Exceptional Items Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI) Extra Ordinary Items Profit/(Loss) before Tax (VII-VIII) Tax Expenses (1) Current Tax (2) Tax Adjustment Previous Year (3) Deffered Tax Profit/(Loss) for the period from continuing operations (IX - X) Profit/(Loss) form discontinuing operations Tax Expenses of discontinuing operations	Revenue from Operations	Revenue from Operations	Revenue from Operations	Particulars 2019 2018 2019		

Notes:

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2019 have been reviewed by the Audit Committee in their Meeting held on 28.01.2020 and approved by the Board of Directors of its Meeting held on 28.01.2020. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place: Mumbai

Date: 28th January, 2020

For Chemo Pharma Laboratories Limited

Ashok Somani Director

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATON OF STANDALONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2019

(Rs. In Thousand)

PARTICULARS	STANDALONE							
	UNAUDITED QUARTER ENDED			NINE MONTHS ENDED		AUDITED YEAR ENDED		
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019		
Reconciliation of Profit After Tax as reported earlier:			1.532					
Net Profit / (Loss) for the Period (as per AS)	683.00	1,785.00	118.00	3,960.00	(364.00)	0.050		
Benefit / (Charge):	-			0,500.00	(304.00)	2,063		
Impact of Deferred Income (Government Grant) Amortized to Income		-						
Impact of Fair Valuation of Financial Instruments	-	_			-			
Impact of Actuarial Gain / Loss Taken OCI	-	_		-	-	-		
Impact of Adjustment of Deferred Tax			-	-	-	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		
Net Profit / (Loss) for the Period (as per AS)	683.00	1,785.00	118.00		-	-		
	000.00	1,785.00	118.00	3,960.00	(364.00)	2,063		

Mumbai, 28th January, 2020



For Chemo Pharma Laboratories Ltd.

Ashok Somani Director